Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Income from Non-Controlling Interests (2022 - 2024)

Historic Income from Non-Controlling Interests for Zentalis Pharmaceuticals (ZNTL) over the last 3 years, with Q1 2024 value amounting to -$28000.0.

  • Zentalis Pharmaceuticals' Income from Non-Controlling Interests rose 3488.37% to -$28000.0 in Q1 2024 from the same period last year, while for Dec 2024 it was -$28000.0, marking a year-over-year increase of 7543.86%. This contributed to the annual value of -$28000.0 for FY2024, which is 7543.86% up from last year.
  • Per Zentalis Pharmaceuticals' latest filing, its Income from Non-Controlling Interests stood at -$28000.0 for Q1 2024, which was up 3488.37% from -$22000.0 recorded in Q4 2023.
  • In the past 5 years, Zentalis Pharmaceuticals' Income from Non-Controlling Interests ranged from a high of -$12000.0 in Q3 2023 and a low of -$160000.0 during Q1 2022
  • Moreover, its 3-year median value for Income from Non-Controlling Interests was -$35000.0 (2022), whereas its average is -$49888.9.
  • Within the past 5 years, the most significant YoY rise in Zentalis Pharmaceuticals' Income from Non-Controlling Interests was 8787.88% (2023), while the steepest drop was 6923.08% (2023).
  • Quarter analysis of 3 years shows Zentalis Pharmaceuticals' Income from Non-Controlling Interests stood at -$13000.0 in 2022, then tumbled by 69.23% to -$22000.0 in 2023, then decreased by 27.27% to -$28000.0 in 2024.
  • Its last three reported values are -$28000.0 in Q1 2024, -$22000.0 for Q4 2023, and -$12000.0 during Q3 2023.